Background
==========

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths in the United States and Canada. The disease is expected to be diagnosed in approximately 142,820 Americans in 2013, and an estimated 50,830 people are expected to die of CRC in that year \[[@B1]\]. In Canada an estimated 23,900 Canadians will be diagnosed with CRC in 2013, and 9,200 Canadians will die of the disease \[[@B2]\].

In the National Polyp Study, colonoscopy with adenoma removal was associated with a reduction in CRC as high as 90% \[[@B3]\]. Recently, however, several reports have questioned whether colonoscopy as practiced in the community reduces CRC and mortality to the same degree as that reported by highly specialized cancer centers \[[@B4]-[@B7]\].

Studies have found that although colonoscopy effectiveness is high for lesions that arise on the left side of the colon, the procedure fails to confer similar levels of protection from CRC incidence and mortality in right-sided lesions. In 2009, a case--control study of colonoscopy in Ontario, Canada, reported that although the procedure reduced mortality from left-sided lesions by about 40%, no reduction in deaths was evident when CRC originated in the right colon \[[@B4]\]. Similarly, in a population-based retrospective analysis from Manitoba, colonoscopy found no reduction in CRC mortality in the case of proximal lesions \[[@B5]\]. A large German, statewide cross-sectional study of colonoscopy found the prevalence of advanced colorectal neoplasms strongly reduced by 67% in left-sided lesions, but this protection did not extend when the lesions were right-sided \[[@B6]\]. A later study by the same authors, which emphasized high-quality colonoscopy, found the procedure to be associated with a reduced risk of 56% for right colonic lesions, which is an improvement over earlier reports, but is less than the 84% reduced risk for CRC the authors observed for left colonic lesions \[[@B7]\].

A number of suggestions have been advanced to explain why colonoscopy may be less effective in the right colon than in the left. The technology is operator-dependent and requires complete endoscopic evaluation, which is more difficult to complete in the right side of the colon**.** Bowel cleansing and preparation for colonoscopy may be less adequate on the right side, making lesions more difficult to visualize. Nonpolypoid flat or depressed lesions are more prevalent in the right than in the left side of the colon, and these are more challenging to identify and remove \[[@B8]\]. There may also be differences in biology between proximal and distal lesions; for example, distal and proximal CRCs show genetic and molecular differences \[[@B9]\].

We previously reported a seven-gene, blood-based biomarker panel for CRC detection \[[@B10]\]. For this current study, we hypothesize that this gene panel, which is a blood-based test, not dependent on localization, preparation or operator technique, can provide a non-biased method for detecting CRC arising in either the right or the left side of the colon.

The test is intended as a pre-screening tool and convenient companion diagnostic test to help those patients who are averse to colonoscopy and to the fecal occult blood test to make an informed decision based on their individual molecular profile. Because of its narrow focus, the test is not expected to alter clinical practice for patients who comply with recommended screening schedules.

Methods
=======

Sample collection procedures and details of methodology for identification of the seven-gene blood-based biomarker panel for CRC were reported in our earlier study \[[@B10]\]. Briefly, 9,199 blood samples were taken from screening colonoscopy subjects at twenty-four centers located in the Greater Toronto Area and surrounding regions and in the United States, between March 2005 and March 2008. Uniformity of collection procedures at the different sites was ensured by the use of identical study protocols, uniform training of personnel, and periodic site monitoring. Informed consent was obtained according to protocols approved by the Research Ethics Board of each of the participating twenty-four clinics and hospitals.

The low incidence of CRC in the colonoscopy screening population made it necessary to recruit additional patients from cancer clinics in Toronto. In these cases, blood samples were collected prior to any treatment, including surgery. Patients enrolled in colonoscopy clinics provided blood prior to colonoscopy. Samples were categorized following review of pathology reports.

Case samples comprised blood samples taken from colonoscopy-confirmed CRC patients who had not undergone CRC treatment. Institutional pathologists determined cancer stage according to the American Joint Committee on Cancer (AJCC) Tumour, Node, and Metastases (TNM) staging system \[[@B11]\]. Controls comprised samples from subjects with no pathology at colonoscopy.

The qRT-PCR training set was composed of 112 well-characterized CRC and 120 control samples (total = 232) taken from the population described above. Cancer and control samples were matched for age, sex, body mass index (BMI) and ethnicity.

An independent blind test set was composed of 410 average-risk subjects following colonoscopy (202 CRC/208 control). Average risk was defined as follows: subjects aged ≥ 50 with no cancer or chemotherapy history, no previous record of colorectal disease (adenomatous polyps, CRC or inflammatory bowel disease) and no first-degree relatives with CRC. Cancer and control samples were matched for sex, BMI and ethnicity. The average age of patients was 3.6 years older than that of control subjects.

Most of the patients and controls who provided samples for qRT-PCR experiments had one or multiple co-morbidities, most commonly, hypertension, hypercholesterolemia, diabetes, arthritis, anemia and allergies. More than 56% of the CRC samples were diagnosed with early stage I and II CRC and 32% with stage III cancer. (Table [1](#T1){ref-type="table"}) This means that approximately 90% of cases were potentially treatable CRC patients, which increases the practical value of the test.

###### 

Available samples

  **Sample \#**    **Training**   **Test**   **Combined**             
  --------------- -------------- ---------- -------------- ---- ----- -----
  TNM I                 19           12           46        16   65    28
  TNM II                20           11           37        18   57    29
  TNM III               21           13           39        25   60    38
  TNM IV                7            5            10        7    17    12
  Unknown               5            1            4         0     9     1
  All Stages            72           42          136        66   208   108
  Control              120          208          328                  

**NB** Two training samples have both left and right cancer.

Blood collection and RNA isolation
----------------------------------

Samples were collected in PAXgene™ tubes (PreAnalytiX) and processed according to the manufacturer's Blood RNA Kit protocol. RNA quality for all samples was assessed using a 2100 Bioanalyzer RNA 6000 Nano Chip (Agilent Technologies). All samples met quality criteria: RIN ≥ 7.0; 28S:18S rRNA ratio ≥ 1.0 and a validated Agilent bioanalyzer scan. RNA quantity was determined by absorbance at 260nm in a DU-640 Spectrophotometer (Beckman Coulter).

Quantitative reverse-transcriptase polymerase chain reaction
------------------------------------------------------------

One microgram of RNA was reverse-transcribed into single-stranded complementary DNA (cDNA) using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a 20μL reaction. For PCR, 20ng cDNA was mixed with QuantiTect® Probe PCR Master Mix (Qiagen), and TaqMan® dual-labeled probe and primers corresponding to the gene of interest and reference gene, in a 25 μL reaction volume. PCR amplification was performed using a 7500 Real-Time PCR System (Applied Biosystems). Each sample was tested in duplicate reactions on the same PCR plate. The run results were subjected to quality control processes, and failed samples were repeated. Samples that failed a second time were excluded from the analysis.

For the blind test set, first, we selected samples with disease status known (in order to balance the sample groups and avoid biases in clinical and demographic characteristics). Selected samples were then randomized and assigned blinded identification prior to the experiment, and data analysis was performed by scientists blinded to the disease status.

The seven-gene panel
--------------------

Details of the characterization and validation of the seven-gene panel to identify CRC have been described previously \[[@B10]\]. In that study a seven-gene panel (*ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1, IL2RB*) discriminated CRC in the training set \[area under the receiver-operating-characteristic curve (AUC ROC), 0.80; accuracy, 73%; sensitivity, 82%; specificity 64%\]. The independent blind test set confirmed performance (AUC ROC, 0.80; accuracy, 71%; sensitivity, 72%; specificity, 70%).

For the present study we re-analyze the previously reported data in order to determine the ability of the seven gene panel not only to identify the presence of CRC but also to identify cancer stages and left- and right-sided colon cancer.

Results
=======

The training set data was used to determine the best coefficients for a logistic regression model using 6 ratios of the 7 genes most discriminative for CRC. This model was then used to predict the CRC risk for the test set samples.

Breaking the data down by cancer stages, we were able to find the same predictive values for left- and right-sided cancers as for CRC detection as in the original paper (Table [2](#T2){ref-type="table"}).

###### 

Correct call rate

                **Training**     **Test**      **1000X 2-Fold**                             
  ------------ -------------- --------------- ------------------ ------------- ------------ ------
  TNM I             63%             92%              61%              44%          67%       66%
  (12/19)         (11/12)         (28/46)           (7/16)         (43.5/65)    (18.6/28)   
  TNM II            70%             91%              81%              89%          79%       89%
  (14/20)         (10/11)         (30/37)          (16/18)         (45.0/57)    (25.9/29)   
  TNM III           86%            100%              74%              84%          83%       90%
  (18/21)         (13/13)         (29/39)          (21/25)         (49.6/60)    (34.3/38)   
  TNM IV            86%            100%              50%             100%          66%       100%
  (6/7)            (5/5)          (5/10)            (7/7)          (11.2/17)    (12.0/12)   
  Unknown           80%            100%              100%             n/a          80%       100%
  (4/5)            (1/1)           (4/4)            (0/0)           (7.2/9)      (1.0/1)    
  All Stages        75%             95%              71%              77%          75%       85%
  (54/72)         (40/42)        (96/136)          (51/66)        (156.5/208)   (91.8/108)  
  Control       64% (77/120)   70% (145/208)    64% (210/328)                               

In this study, CRC detection sensitivity was generally higher for right-sided cancer except in the case of TNM stage I in the test set. However, this finding may be simply a sampling issue. To resolve this question, we combined all training and test set samples and performed 2-fold cross validation, iterated 1000 times. This process partitions the samples into 2 halves such that that the coefficients of the model are fitted to the training half and applied to the test half.

The results for all the test halves after 1000 permutations represent a less biased estimate of the performance of the gene panel. As expected, the lower sensitivity for right-sided TNM I as compared with left-sided TNM I cancers is no longer observed in the cross-validated results. Overall, right-sided lesions are detected at a higher sensitivity than left-sided lesions; however, there are fewer right-sided samples, so the observed higher sensitivity may not be statistically significant. As can be seen from the box and whisker plots of the distribution of the prediction scores, the 98% confidence intervals show considerable overlap both across all TNM stages and for left and right sided cancers (Figure [1](#F1){ref-type="fig"}).

![**Distribution of prediction scores from 1000 iterations of 2-fold cross-validation analysis.** Boxes indicate the central 50 percentile with whiskers showing the extent of the 98 percentile.](1756-9966-32-44-1){#F1}

The panel detected left-sided (75%, 156/208) and right-sided (85%, 92/108) lesions with an overall sensitivity of 78% (248/316) at a specificity of 64% (210/328). Treatable cancer (stages I to III) was detected with a left-sided lesion sensitivity of 76% (138/182) and a right-sided sensitivity of 83% (79/95).

Discussion
==========

In several studies we have shown that gene signatures obtained using blood mRNA can identify a variety of conditions occurring in various sites throughout the body, including heart failure \[[@B12]\], inflammatory bowel disease \[[@B13],[@B14]\], psychiatric disorders \[[@B15]-[@B17]\] and various cancers \[[@B10],[@B18]-[@B20]\]. These studies suggest that blood cells may act as "sentinels" that can mirror health or disease anywhere in the body. Blood transcriptomic signatures thus reflect molecular changes regardless of where they occur in the body.

We have also recently reported a blood test based on the performance characteristics of a seven-gene panel that enables us to assess a patient's current risk of having CRC \[[@B10]\]. As a blood test similar to other routine blood tests, the assay overcomes a number of reported limitations to patient acceptance of CRC screening using currently utilized tests. Such barriers include patients' fear of pain, inconvenience, unpleasantness, pre-procedure colon evacuation methods, the need to take time off work and to be sedated, risks such as bowel perforation, bleeding and other complications (for colonoscopy and other endoscopic methods) and patient embarrassment and beliefs that methods are unsanitary, unpleasant or inconvenient (fecal tests) \[[@B21]-[@B27]\]. By contrast, a simple, convenient blood test should encourage increased compliance with screening recommendations.

In this study we use the same seven-gene panel to address another issue limiting the effectiveness of colonoscopy: the right-sided bias observed in such technology. CRC can arise in either the right, proximal colon or the left, distal colon. The former includes the cecum, ascending colon, hepatic flexure and transverse colon, and the latter the descending and sigmoid colon and rectum. Colonoscopy tends to bias towards detection on the left side, for reasons both technical and biological. The blood-based test for CRC reported in this study would have the effect of reducing such bias, thus potentially increasing detection rates for right sided lesions.

This pre-screening test is mainly intended for detection of TNM I to TNM III patients**.** For these patients, test sensitivity is 76% for left-sided cancers and 84% for right-sided cancers. TNM IV stage patients are likely to be diagnosed by conventional means and are less likely to benefit much from intervention.

Conclusion
==========

This study finds that detection of CRCs using mRNA biomarkers from whole blood is equally sensitive to treatable TNM I -- III lesions located throughout the colon (Figure [2](#F2){ref-type="fig"}). These findings support the use of the seven-gene panel as a non-biased method for CRC detection for both left and right-sided lesions.

![**Prediction sensitivity for all CRC at each stage.** Figures inside the bars show the ratios of average positive calls from 1000 iterations of 2-fold cross validation analysis.](1756-9966-32-44-2){#F2}
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